FEATURES OF THE TREATMENT OF PATIENTS WITH HER-2/NEU+ TYPE OF BREAST CANCER

Abstract

Research work was done in 106 patients with breast cancer stage I-II with 2/neu+ (positive) who were treated chemically in inpatient conditions, and a control group was selected from 26 patients diagnosed with 2/neu+ (negative) breast cancer during 2015-2020 at the Samarkand region branch of the Republican specialized oncology and radiology scientific-practical medical center. As a result, p53, VEGF and Ki-67 were found in 73.3, 80.0 and 76.7% of cases in the study of molecular-biological markers of tumors; The presence of Bcl-2 markers, the presence of EGFR in 36.7 and 30.0% of cases was determined. The greatest prognostic value in evaluating the effectiveness of the treatment was determined by the following markers: p53, VEGF, Ki-67, and correction of the therapy used in the treatment was recommended. The analysis of the main parameters of the immune system, clinical and biochemical parameters indicated the need for immunotherapy and the effectiveness of polyoxydonium in the complex treatment of Her-2 patients was proven.

PDF